Changes in Beneficial Ownership · 4
Neuronetics, Inc.
STIMNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-11-12
- Issuer
- Neuronetics, Inc.
- Issuer CIK
- 0001227636
- Trading symbol
- STIM
Reporting owner 1
- Name
- Cucuz Sasha
- Reporting owner CIK
- 0002004858
- Relationship
- Director
- Address
- C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN, PA, 19355
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | 2026-11-12 | J · Form 4[F1] | 625,000 | A | 1.60 | 625,000[F2] | I | By 2144304 Ontario Inc. |
| Common Stock | 2026-11-13 | A · Form 4 | 370,370 | A | 1.35 | 995,370[F2] | I | By 2144304 Ontario Inc. |
Table key
- J · Form 4
- Other acquisition or disposition; see explanation
- A
- Acquired
- I
- Indirect
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
Non-derivative holdings
| Security | Amount owned | Ownership | Nature of ownership |
|---|---|---|---|
| Common Stock | 1,542,798 | D | |
| Common Stock | 2,042[F2] | I | By Greybrook Realty Partners Inc. |
| Common Stock | 516,084[F2] | I | By Greybrook Value-Add Equity Inc. |
Table key
- D
- Direct
- I
- Indirect
Footnotes
- F1
- On November 12, 2026, the Reporting Person purchased 625,000 shares of the Issuer's Common Stock in connection with a firm commitment underwritten offering.↩ 1
- F2
- The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.↩ 1↩ 2↩ 3↩ 4
Signature 1
- Signed
- /s/ Francis Brown, as Attorney-in-Fact
- Date
- 2026-11-16
Company context
Neuronetics, Inc. is a leader in interventional mental health, combining innovative treatment technologies with direct patient care. Through its NeuroStar® Advanced Therapy system, the company is a leading provider of transcranial magnetic stimulation (“TMS”) treatment and, through Greenbrook, operates one of the largest interventional psychiatry clinic networks in the United States, offering both TMS and SPRAVATO® therapies. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. NeuroStar Advanced Therapy is the leading TMS treatment for major depressive disorder (“MDD”) in adults and is backed by what we believe is the largest clinical data set of any TMS treatment system for depression. Greenbrook treatment centers also offer SPRAVATO® (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with MDD with acute suicidal ideation or behavior in conjunction with an oral antidepressant. 1